Wolf-Dieter Schleuning

Title: Wolf-Dieter Schleuning: Innovator in Fibrinolytic Therapy

Introduction

Wolf-Dieter Schleuning is a notable inventor based in New York, NY (US). He has made significant contributions to the field of medical science, particularly in the area of fibrinolytic therapy. His work has implications for treating conditions related to blood clotting, which can be critical in various medical scenarios.

Latest Patents

Wolf-Dieter Schleuning holds a patent for a human serum plasminogen activator. This plasminogen proactivator has been isolated from mammalian and avian plasma, especially human plasma. It is characterized as a single, electrophoretically and immunologically homogeneous protein within a given species. The activator serves as a catalyst to initiate fibrinolytic activity in plasma, making it useful for controlling clotting in cases such as venous thrombosis or arterial occlusion. Additionally, it aids in diagnosing conditions that predispose individuals to thromboembolic phenomena. The proactivator boasts a long useful in vivo half-life, providing a reservoir for maintaining the fibrinolytic potential of blood. He has 1 patent to his name.

Career Highlights

Wolf-Dieter Schleuning is affiliated with The Rockefeller University, where he has conducted much of his research. His work has been instrumental in advancing the understanding of fibrinolytic processes and their applications in medicine.

Collaborations

Some of his notable coworkers include Edward Reich and Arabinda Guha. Their collaborative efforts have contributed to the advancements in the field of fibrinolytic therapy.

Conclusion

Wolf-Dieter Schleuning's innovative work in developing a human serum plasminogen activator highlights his significant contributions to medical science. His research continues to impact the treatment of blood clotting disorders, showcasing the importance of innovation in healthcare.